Shanghai Henlius Biotech (HKG:2696) will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according to a Thursday press release by Henlius.
The Saudi Arabian company, owned by the Fakeeh family, together with Henlius, will market adalimumab and bevacizumab products, in the Middle East, North Africa, and Türkiye, according to the Hong Kong-listed company.
Adalimumab is indicated for rheumatoid arthritis and inflamed joints, while bevacizumab is a cancer treatment.
The two companies will also jointly develop pembrolizumab, another antibody for melanoma, lung cancer, Hodgkin lymphoma, and cancers of the stomach, cervix, head and neck
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。